Clinical Trials in Adult ANLL: An Overview

  • Michael Rooney
Part of the Developments in Oncology book series (DION, volume 33)

Abstract

Tremendous advances have been made over the past 20 years in the treatment of acute non lymphocytic leukemia (ANLL) in adults. This chapter will provide a historical perspective on the emergence of modern chemotherapy against ANLL. By reviewing past and current clinical trials, an appreciation of the stepwise progress which has been made in the understanding and management of this disease may be gained.

Keywords

Leukemia Prednisone Cytosine Vincristine Anthracycline 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Freireich EJ et al: Cytarabine for acute leukemia in adults. Arch. Inter. Med. 133: 251–259, 1974.CrossRefGoogle Scholar
  2. 2.
    Ellison RR et al: Arabinosyl cytosine: A useful agent in the treatment of acute leukemia in adults. Blood 32: 507–523, 1968.PubMedGoogle Scholar
  3. 3.
    Weil M, Glidewell OJ, Jaquillat C: Daunorubicin in the therapy of acute granulocytic leukemia. Cancer Res. 33: 921–928, 1973.PubMedGoogle Scholar
  4. 4.
    Wiernik PH, Serpick AA: A randomized clinical trial of daunorubicin and a combination of prednisone, vincristine, 6-mercaptopurine and methotrexate in adult nonlymphocytic leukemia. Cancer Res. 32: 2023–2026, 1972.PubMedGoogle Scholar
  5. 5.
    Boggs DR: The kinetics of neutrophilic leukocytes in health and disease. Semin. Hematol. 4: 359–386, 1967.PubMedGoogle Scholar
  6. 6.
    Carey RW et al: Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine or daunorubicin in acute myelocytic leukemia. Cancer 36: 1560–1566, 1975.PubMedCrossRefGoogle Scholar
  7. 7.
    Wiernik PH, Glidewell OJ et al: A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine and a combination of the three agents for the treatment of acute myelocytic leukemia. Med. Ped. Onc. 6: 261–277, 1979.CrossRefGoogle Scholar
  8. 8.
    Weirnik PH, Schimpff SC et al: Randomized clinical comparison of daunorubicin alone with a combination of daunorubicin, cytosine arabinoside, 6-thioguanine and pyrimethamine for the treatment of acute nonlymphocytic leukemia. Cancer Treat. Rep. 60: 41–53, 1976.Google Scholar
  9. 9.
    Clarkson BD: Acute myelocytic leukemia in adults. Cancer 30: 1572–1582, 1972.PubMedCrossRefGoogle Scholar
  10. 10.
    Yates JW, Holland JF et al: Cytosine arabinoside and daunorubicin therapy in acute nonlymphocytic leukemia. Cancer Chem. Rep. 57 (4): 485–488, 1973.Google Scholar
  11. 11.
    Rodriguez V, Hart JS, Freireich EJ et al: POMP combination chemotherapy of adult acute leukemia. Cancer 32: 69–75, 1973.PubMedCrossRefGoogle Scholar
  12. 12.
    Bodey GP, Coltman CA et al: Chemotherapy of acute leukemia. Arch. Intern. Med. 133: 260–266, 1974.PubMedCrossRefGoogle Scholar
  13. 13.
    Vaughan WP, Karp JE, Burke PJ: Long chemotherapy-free remissions after single cycle timed sequential chemotherapy for acute myelocytic leukemia. Cancer 45: 859–865, 1980.PubMedCrossRefGoogle Scholar
  14. 14.
    Lewis JP, Linman JW et al: Randomized clinical trial of cytosine arabinoside and 6-thioguanine in remission induction and consolidation of adult nonlymphocytic acute leukemia. Cancer 39: 1387–1396, 1977.PubMedCrossRefGoogle Scholar
  15. 15.
    Preisler H, Bjornsson S et al: Remission induction in acute nonlymphocytic leukemia: Comparison of a seven-day and ten-day infusion of cytosine arabinoside in combination with adriamycin. Med. Ped. Onc. 7: 269–275, 1979.CrossRefGoogle Scholar
  16. 16.
    Weinstein HJ, Mayer RJ et al: Treatment of acute myelogenous leukemia in children and adults. NEJM 303: 473–478, 1980.PubMedCrossRefGoogle Scholar
  17. 16a.
    Keating MJ, Smith TL et al: Four-year experience with anthracycline, cytosine arabinoside, vincristine and prednisone combination chemotherapy in 325 adults with acute leukemia. Cancer 47: 2779–2788, 1981.PubMedCrossRefGoogle Scholar
  18. 17.
    Lewis JP, Meyers F et al: Continuous infusion daunomycin in remission induction of acute nonlymphocytic leukemia. Blood 62: 205a, 1983.Google Scholar
  19. 18.
    Gale RP, Cline MJ: High remission induction rate in acute myeloid leukemia. Lancet (1): 497–499, 1977.Google Scholar
  20. 19.
    Rees JKH, Sandler RM et al: Treatment of acute myeloid leukemia with a triple cytotoxic regime: DAT. Br. J. Cancer 36: 770–776, 1977.PubMedCrossRefGoogle Scholar
  21. 20.
    Rai KR, Holland JF, Glidewell OJ: Improvement of remission induction of acute myelocytic leukemia. Proc. ASCO 16: 265, 1975.Google Scholar
  22. 21.
    Chang P, Wiernik PH, Reich SD et al: Prediction of response to cytosine arabinoside and daunorubicin in acute nonlymphocytic leukemia. In: Therapy of Acute Leukemias, Mandelli (ed), Rome, Italy, Lombardo Editore, 1979, pp. 430–433.Google Scholar
  23. 22.
    Yates J, Glidewell OJ, Wiernik PH et al: Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: A CALGB study. Blood 60: 454–462, 1982.PubMedGoogle Scholar
  24. 22.
    Yates J, Glidewell OJ, Wiernik PH et al: Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: A CALGB study. Blood 60: 454–462, 1982.PubMedGoogle Scholar
  25. 24.
    Peterson BA, Bloomfield CD: Long term disease free survival in acute nonlymphocytic leukemia. Blood 57: 1144 1147, 1981.Google Scholar
  26. 25.
    Gale RP, Foon KA et al: Intensive chemotherapy for acute myelogenous leukemia. Annals Int. Med. 94: 753–757, 1981.Google Scholar
  27. 26.
    Weinstein HJ, Mayer RJ et al: Chemotherapy for acute mye-logenous leukemia in children and adults: VAPA update. Blood 62: 315–319, 1983.PubMedGoogle Scholar
  28. 27.
    Preisler H, Kirshner J, Raza A, Davis R: Comparison of 3 remission induction regimens for the treatment of acute nonlymphocytic leukemia. Blood 62: 206a, 1983.Google Scholar
  29. 28.
    Preisler H, Anderson K et al: Comparison of survival of patients with acute nonlymphocytic leukemia receiving maintenance chemotherapy or bone marrow transplantation in 1st remission. Proc. ASCO 2: 177, 1983.Google Scholar
  30. 29.
    Champlin R, Zighelboim W et al: Treatment of acute myelogenous leukemia — bone marrow transplantation vs. consolidation chemotherapy. Proc. ASCO 2: 180, 1983.Google Scholar
  31. 30.
    Foon KA, Gale RP: Controversies in the therapy of acute myelogenous leukemia. Amer. J. Med. 72: 963–979, 1982.PubMedCrossRefGoogle Scholar
  32. 31.
    Dutcher JP, Markus S, Wiernik PH et al: Intensive maintenance therapy in acute nonlymphocytic leukemia. Blood 62: 201a, 1983.Google Scholar
  33. 32.
    Freireich EJ, Keating MJ, Gehan EA et al: Therapy of acute myelogenous leukemia. Cancer 42: 874–882, 1978.PubMedCrossRefGoogle Scholar
  34. 33.
    Hines JD, Oken MM, Mazza J et al: High dose cytosine arabinoside and M-AMSA induction and consolidation in acute nonlymphocytic leukemia. Blood 62: 203a, 1983.Google Scholar
  35. 34.
    Arlin ZA, Flomenberg N et al: Treatment of acute leukemia in relapse with AMSA in combination with cytosine arabinoside and thioguanine. Cancer Clin. Trials 4: 317–321, 1981.Google Scholar
  36. 35.
    McCredie KB, Keating MJ, Estey EH et al: Use of AMSA, cytosine arabinoside, vincristine, prednisone combination in poor risk patients in acute leukemia. Proc. AACR 22: 479, 1981.Google Scholar
  37. 36.
    Kahn SB, Conroy JF, Bulova S et al: AMSA and 5-azacytidinc therapy of acute leukemia. Blood 58: 143a, 1981.Google Scholar
  38. 37.
    Hurd DD, Peterson BA, Bloomfield CD: AMSA, VP-16, cytosine arabinoside, and 6-thioguanine in the treatment of relapsec and refractory acute nonlymphocytic leukemia. Blood 58: 142a, 1981.Google Scholar
  39. 38.
    Hines JD, Oken MM, Mazza J et al: High dose cytosine arabinoside and AMSA in refractory acute nonlymphocytic leukemia. Blood 58: 142a, 1981.Google Scholar
  40. 39.
    Herzig RH, Wolff SN, Karanes C et al: High dose cytosine arabinoside therapy for refractory leukemia. Blood 62: 361–369, 1983.PubMedGoogle Scholar
  41. 40.
    Wolff SN: High dose cytosine arabinoside and daunorubicin for acute nonlymphocytic leukemia in first remission. Proc. ASCO 25: 1984 (in press).Google Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1985

Authors and Affiliations

  • Michael Rooney

There are no affiliations available

Personalised recommendations